This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Albany Molecular Research Inc (AMRI)

NASDAQ: Health Care

Company Balance Sheet
Dec 2013 Dec 2012 Dec 2011 Dec 2010
Assets
Cash and Equivalents 175.93M 23.29M 19.98M 25.75M
Receivables 59.74M 50.68M 40.66M 47.82M
Inventories 31.99M 28.22M 26.00M 27.10M
Other Current Assets 0.00 0.00 0.00 0.00
Total Current Assets 279.02M 113.42M 100.56M 134.05M
Property, Plant & Equipment, Gross 294.76M 294.49M 296.63M 294.56M
Accumulated Depreciation & Depletion 166.99M 158.97M 146.83M 131.35M
Property, Plant & Equipment, Net 127.78M 135.52M 149.80M 163.21M
Intangibles 3.04M 3.06M 2.98M 3.94M
Other Non-Current Assets 33.38M 7.33M 2.36M 6.61M
Total Non-Current Assets 166.25M 149.44M 162.51M 191.06M
Liabilities & Shareholder Equity
Total Assets 445.27M 262.86M 263.07M 325.11M
Accounts Payable 24.18M 18.19M 20.42M 24.72M
Short Term Debt 1.02M 776.00K 2.84M 1.48M
Other Current Liabilities 12.70M 11.64M 4.08M 9.80M
Total Current Liabilities 43.90M 35.99M 37.98M 54.64M
Long Term Debt 123.14M 7.23M 3.00M 11.74M
Deferred Income Taxes 631.00K 753.00K 733.00K 0.00
Other Non-Current Liabilities 31.90M 12.76M 14.92M 14.99M
Minority Interest 0.00 0.00 0.00 0.00
Total Non-Current Liabilities 155.66M 20.74M 18.66M 26.73M
Total Liabilities 199.56M 56.72M 56.63M 81.36M
Preferred Stock Equity 0.00 0.00 0.00 0.00
Common Stock Equity 245.70M 206.14M 206.43M 243.74M
Common Par 370.00K 363.00K 360.00K 357.00K
Additional Paid In Capital 235.81M 207.78M 206.07M 203.96M
Cumulative Translation Adjustment 0.00 0.00 0.00 0.00
Retained Earnings 87.86M 75.18M 78.95M 111.25M
Treasury Stock -67.05M -66.89M -66.89M -66.89M
Other Equity Adjustments -11.28M -10.30M -12.07M -4.94M
Total Capitalization 368.84M 213.37M 209.44M 255.48M
Total Equity 245.70M 206.14M 206.43M 243.74M
Total Liabilities & Stock Equity 445.27M 262.86M 263.07M 325.11M
Total Common Shares Outstanding 31.60M 30.92M 30.60M 30.26M
Preferred Shares 0.00 0.00 0.00 0.00
Treasury Shares 5.42M 5.41M 5.41M 5.41M
Basic Weighted Shares Outstanding 30.91M 30.32M 29.96M 30.66M
Diluted Weighted Shares Outstanding 30.91M 30.32M 29.96M 30.66M
Number of Employees 1282 1329 1389 1421
Number of Part-Time Employees 0 0 0 0
AMRI News

AMRI Albany Molecular Research Inc

Analysts Ratings for AMRI

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 1 1 0 0
Moderate Buy 1 1 1 1
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 1 1 1
GET AMRI ANALYST REPORT

Brokerage Partners

AMRI Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs